Zhang Jiachao's team: intestinal phage markers for colorectal cancer

1. 317 metagenomic samples from 3 countries were included, and 5 phage markers enriched in colorectal cancer (CRC) were identified by random forest model, including Peptacetobacter hiranonis phage, Micromonas phage and 3 specific phage markers. Fusobacterium nucleatum phage, differentiated between CRC and controls (AUC=0. 8616); 2. and validated in a cohort of 80 samples in 2 countries (AUC=0. 8197); 3. in ulcerative colitis (UC, n= 76) and Crohn's disease (CD, n=88) cohorts, phage markers were able to distinguish CRC from UC well (AUC=0. 7802), but were less effective for CD (AUC=0. 4800) . Editor's recommendation mildbreeze In the study of microbiome markers in colorectal cancer (CRC), there are relatively few phage-related studies . The team of Zhang Jiachao from Hainan University recently published an article on the Microbiology spectrum, reporting 5 potential CRC phage markers, which can better distinguish CRC from control populations, bringing new inspiration for microbiome-based CRC diagnosis and phage therapy . Microbiology spectrum [IF:7. 171] Expanding the Colorectal Cancer Biomarkers Based on the Human Gut Phageome 10. 1128/Spectrum. 00090-21 　　2021-12-22, Article 　　Abstract: 　　With the increasing prevalence of colorectal cancer (CRC), extending the present biomarkers for the diagnosis of colorectal cancer is crucial. Previous studies have highlighted the importance of bacteriophages in gastrointestinal diseases, suggesting the potential value of gut phageome in early CRC diagnostic. Here, based on 317 metagenomic samples of three discovery cohorts collected from China (Hong Kong), Austria, and Japan, five intestinal bacteriophages, including Fusobacterium nucleatum, and Parvimonas micra phages were identified as potential CRC biomarkers. The five CRC enriched bacteriophagic markers classified patients from controls with an area under the receiver-operating characteristics curve (AUC) of 0. 8616 across different populations. Subsequently, we used a total of 80 samples from China (Hainan) and Italy for validation. The AUC of the validation cohort is 0. 8197. Moreover, to further explore the specificity of the five intestinal bacteriophage biomarkers in a broader background, we performed a confirmatory meta-analysis using two inflammatory bowel disease cohorts, ulcerative colitis (UC) and Crohn's disease ( CD). Excitingly, we observed that the five CRC-enriched phage markers also exhibited high discrimination in UC (AUC = 78. 02%). Unfortunately, the five CRC-rich phage markers did not show high resolution in CD (AUC = 48. 00%) . The present research expands the potential of microbial biomarkers in CRC diagnosis by building a more accurate classification model based on the human gut phageome, providing a new perspective for CRC gut phagotherapy. Worldwide, by 2020, colorectal cancer has become the third most common cancer after lung and breast cancer. Phages are strictly host-specific, and this specificity makes them more accurate as biomarkers, but phage biomarkers for colorectal cancer have not been thoroughly explored. Therefore, it is crucial to extend the existing phage biomarkers for the diagnosis of colorectal cancer. Here, we innovatively constructed a relatively accurate prediction model, including: three discovery cohorts, two additional validation cohorts and two cross-disease cohorts. A total of five possible biomarkers of intestinal bacteriophages were obtained. They are Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, and Parvimonas micra Phage. This study aims at identifying fine-scale species-strain level phage biomarkers for colorectal cancer diseases,so as to expand the existing CRC biomarkers and provide a new perspective for intestinal phagocytosis therapy of colorectal cancer. First Authors: Siyuan Shen Correspondence Authors: Jiachao Zhang All Authors: Siyuan Shen,Dongxue Huo,Chenchen Ma,Shuaiming Jiang,Jiachao Zhang   Disclaimer: This article only represents the author's personal opinion and has nothing to do with China Probiotics Network . Its originality and the text and content stated in the text have not been verified by this site, and this site does not make any guarantee or commitment to the authenticity, completeness and timeliness of this text and all or part of its content and text. Readers are only for reference and please Verify the relevant content yourself .   Copyright Notice 1. Some articles reproduced on this site are not original, and their copyright and responsibility belong to the original author . 2. All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and the source and author are clearly indicated. Media or individuals who do not wish to be reprinted can contact us for infringing information that can provide sufficient evidence. , bio149 will be deleted within 12 hours after confirmation . 3. Users are welcome to submit original articles to 86371366@qq. com, which will be published on the homepage after review, and the copyright and responsibility of the articles belong to the sender .

1.
317 metagenomic samples from 3 countries were included, and 5 phage markers enriched in colorectal cancer (CRC) were identified by random forest model, including Peptacetobacter hiranonis phage, Micromonas phage and 3 specific phage markers.
Fusobacterium nucleatum phage, differentiated between CRC and controls (AUC=0.
8616);

　　2.
and validated in a cohort of 80 samples in 2 countries (AUC=0.
8197);

　　3.
in ulcerative colitis (UC, n= 76) and Crohn's disease (CD, n=88) cohorts, phage markers were able to distinguish CRC from UC well (AUC=0.
7802), but were less effective for CD (AUC=0.
4800)
.


　　Editor's recommendation

　　mildbreeze

　　In the study of microbiome markers in colorectal cancer (CRC), there are relatively few phage-related studies
.
The team of Zhang Jiachao from Hainan University recently published an article on the Microbiology spectrum, reporting 5 potential CRC phage markers, which can better distinguish CRC from control populations, bringing new inspiration for microbiome-based CRC diagnosis and phage therapy
.


　　Microbiology spectrum　　

　　Expanding the Colorectal Cancer Biomarkers Based on the Human Gut Phageome

　　10.
1128/Spectrum.
00090-21

　　2021-12-22, Article

　　Abstract:

　　With the increasing prevalence of colorectal cancer (CRC), extending the present biomarkers for the diagnosis of colorectal cancer is crucial.
Previous studies have highlighted the importance of bacteriophages in gastrointestinal diseases, suggesting the potential value of gut phageome in early CRC diagnostic.
Here, based on 317 metagenomic samples of three discovery cohorts collected from China (Hong Kong), Austria, and Japan, five intestinal bacteriophages, including Fusobacterium nucleatum, and Parvimonas micra phages were identified as potential CRC biomarkers.
The five CRC enriched bacteriophagic markers classified patients from controls with an area under the receiver-operating characteristics curve (AUC) of 0.
8616 across different populations.
Subsequently, we used a total of 80 samples from China (Hainan) and Italy for validation.
The AUC of the validation cohort is 0.
8197.
Moreover, to further explore the specificity of the five intestinal bacteriophage biomarkers in a broader background, we performed a confirmatory meta-analysis using two inflammatory bowel disease cohorts, ulcerative colitis (UC) and Crohn's disease ( CD).
Excitingly, we observed that the five CRC-enriched phage markers also exhibited high discrimination in UC (AUC = 78.
02%).
Unfortunately, the five CRC-rich phage markers did not show high resolution in CD (AUC = 48.
00%) .
The present research expands the potential of microbial biomarkers in CRC diagnosis by building a more accurate classification model based on the human gut phageome, providing a new perspective for CRC gut phagotherapy.
Worldwide, by 2020, colorectal cancer has become the third most common cancer after lung and breast cancer.
Phages are strictly host-specific, and this specificity makes them more accurate as biomarkers, but phage biomarkers for colorectal cancer have not been thoroughly explored.
Therefore, it is crucial to extend the existing phage biomarkers for the diagnosis of colorectal cancer.
Here, we innovatively constructed a relatively accurate prediction model, including: three discovery cohorts, two additional validation cohorts and two cross-disease cohorts.
A total of five possible biomarkers of intestinal bacteriophages were obtained.
They are Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, and Parvimonas micra Phage.
This study aims at identifying fine-scale species-strain level phage biomarkers for colorectal cancer diseases,so as to expand the existing CRC biomarkers and provide a new perspective for intestinal phagocytosis therapy of colorectal cancer.


First Authors:
Siyuan Shen

Correspondence Authors:
Jiachao Zhang

All Authors:
Siyuan Shen,Dongxue Huo,Chenchen Ma,Shuaiming Jiang,Jiachao Zhang

---

1.
317 metagenomic samples from 3 countries were included, and 5 phage markers enriched in colorectal cancer (CRC) were identified by random forest model, including Peptacetobacter hiranonis phage, Micromonas phage and 3 specific phage markers.
Fusobacterium nucleatum phage, differentiated between CRC and controls (AUC=0.
8616);

　　2.
and validated in a cohort of 80 samples in 2 countries (AUC=0.
8197);

　　3.
in ulcerative colitis (UC, n= 76) and Crohn's disease (CD, n=88) cohorts, phage markers were able to distinguish CRC from UC well (AUC=0.
7802), but were less effective for CD (AUC=0.
4800)
.


　　Editor's recommendation

　　mildbreeze

　　In the study of microbiome markers in colorectal cancer (CRC), there are relatively few phage-related studies
.
The team of Zhang Jiachao from Hainan University recently published an article on the Microbiology spectrum, reporting 5 potential CRC phage markers, which can better distinguish CRC from control populations, bringing new inspiration for microbiome-based CRC diagnosis and phage therapy
.


　　Microbiology spectrum　　

　　Expanding the Colorectal Cancer Biomarkers Based on the Human Gut Phageome

　　10.
1128/Spectrum.
00090-21

　　2021-12-22, Article

　　Abstract:

　　With the increasing prevalence of colorectal cancer (CRC), extending the present biomarkers for the diagnosis of colorectal cancer is crucial.
Previous studies have highlighted the importance of bacteriophages in gastrointestinal diseases, suggesting the potential value of gut phageome in early CRC diagnostic.
Here, based on 317 metagenomic samples of three discovery cohorts collected from China (Hong Kong), Austria, and Japan, five intestinal bacteriophages, including Fusobacterium nucleatum, and Parvimonas micra phages were identified as potential CRC biomarkers.
The five CRC enriched bacteriophagic markers classified patients from controls with an area under the receiver-operating characteristics curve (AUC) of 0.
8616 across different populations.
Subsequently, we used a total of 80 samples from China (Hainan) and Italy for validation.
The AUC of the validation cohort is 0.
8197.
Moreover, to further explore the specificity of the five intestinal bacteriophage biomarkers in a broader background, we performed a confirmatory meta-analysis using two inflammatory bowel disease cohorts, ulcerative colitis (UC) and Crohn's disease ( CD).
Excitingly, we observed that the five CRC-enriched phage markers also exhibited high discrimination in UC (AUC = 78.
02%).
Unfortunately, the five CRC-rich phage markers did not show high resolution in CD (AUC = 48.
00%) .
The present research expands the potential of microbial biomarkers in CRC diagnosis by building a more accurate classification model based on the human gut phageome, providing a new perspective for CRC gut phagotherapy.
Worldwide, by 2020, colorectal cancer has become the third most common cancer after lung and breast cancer.
Phages are strictly host-specific, and this specificity makes them more accurate as biomarkers, but phage biomarkers for colorectal cancer have not been thoroughly explored.
Therefore, it is crucial to extend the existing phage biomarkers for the diagnosis of colorectal cancer.
Here, we innovatively constructed a relatively accurate prediction model, including: three discovery cohorts, two additional validation cohorts and two cross-disease cohorts.
A total of five possible biomarkers of intestinal bacteriophages were obtained.
They are Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, and Parvimonas micra Phage.
This study aims at identifying fine-scale species-strain level phage biomarkers for colorectal cancer diseases,so as to expand the existing CRC biomarkers and provide a new perspective for intestinal phagocytosis therapy of colorectal cancer.


First Authors:
Siyuan Shen

Correspondence Authors:
Jiachao Zhang

All Authors:
Siyuan Shen,Dongxue Huo,Chenchen Ma,Shuaiming Jiang,Jiachao Zhang

---

1.
317 metagenomic samples from 3 countries were included, and 5 phage markers enriched in colorectal cancer (CRC) were identified by random forest model, including Peptacetobacter hiranonis phage, Micromonas phage and 3 specific phage markers.
Fusobacterium nucleatum phage, differentiated between CRC and controls (AUC=0.
8616); 2.
and validated in a cohort of 80 samples in 2 countries (AUC=0.
8197); 3.
in ulcerative colitis (UC, n= 76) and Crohn's disease (CD, n=88) cohorts, phage markers were able to distinguish CRC from UC well (AUC=0.
7802), but were less effective for CD (AUC=0.
4800)
.
Editor's recommendation mildbreeze In the study of microbiome markers in colorectal cancer (CRC), there are relatively few phage-related studies
.
The team of Zhang Jiachao from Hainan University recently published an article on the Microbiology spectrum, reporting 5 potential CRC phage markers, which can better distinguish CRC from control populations, bringing new inspiration for microbiome-based CRC diagnosis and phage therapy
.
Microbiology spectrum[IF:7.
171] Expanding the Colorectal Cancer Biomarkers Based on the Human Gut Phageome 10.
1128/Spectrum.
00090-21 2021-12-22, Article Abstract:With the increasing prevalence of colorectal cancer (CRC), extending the present biomarkers for the diagnosis of colorectal cancer is crucial.
Previous studies have highlighted the importance of bacteriophages in gastrointestinal diseases, suggesting the potential value of gut phageome in early CRC diagnostic.
Here, based on 317 metagenomic samples of three discovery cohorts collected from China (Hong Kong), Austria, and Japan, five intestinal bacteriophages, including Fusobacterium nucleatum, and Parvimonas micra phages were identified as potential CRC biomarkers.
The five CRC enriched bacteriophagic markers classified patients from controls with an area under the receiver-operating characteristics curve (AUC) of 0.
8616 across different populations.
Subsequently, we used a total of 80 samples from China (Hainan) and Italy for validation.
The AUC of the validation cohort is 0.
8197.
Moreover, to further explore the specificity of the five intestinal bacteriophage biomarkers in a broader background, we performed a confirmatory meta-analysis using two inflammatory bowel disease cohorts, ulcerative colitis (UC) and Crohn's disease ( CD).
Excitingly, we observed that the five CRC-enriched phage markers also exhibited high discrimination in UC (AUC = 78.
02%).
Unfortunately, the five CRC-rich phage markers did not show high resolution in CD (AUC = 48.
00%) .
The present research expands the potential of microbial biomarkers in CRC diagnosis by building a more accurate classification model based on the human gut phageome, providing a new perspective for CRC gut phagotherapy.
Worldwide, by 2020, colorectal cancer has become the third most common cancer after lung and breast cancer.
Phages are strictly host-specific, and this specificity makes them more accurate as biomarkers, but phage biomarkers for colorectal cancer have not been thoroughly explored.
Therefore, it is crucial to extend the existing phage biomarkers for the diagnosis of colorectal cancer.
Here, we innovatively constructed a relatively accurate prediction model, including: three discovery cohorts, two additional validation cohorts and two cross-disease cohorts.
A total of five possible biomarkers of intestinal bacteriophages were obtained.
They are Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, Fusobacterium nucleatum Phage, and Parvimonas micra Phage.
This study aims at identifying fine-scale species-strain level phage biomarkers for colorectal cancer diseases,so as to expand the existing CRC biomarkers and provide a new perspective for intestinal phagocytosis therapy of colorectal cancer.


First Authors:
Siyuan Shen

Correspondence Authors:
Jiachao Zhang

All Authors:
Siyuan Shen,Dongxue Huo,Chenchen Ma,Shuaiming Jiang,Jiachao Zhang

---